Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SCPH 
Scpharmaceuticals Inc (SCPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SCPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.03% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 295.23M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 6 | Beta 0.39 | 52 Weeks Range 1.94 - 6.28 | Updated Date 08/29/2025 |
52 Weeks Range 1.94 - 6.28 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.29 | Actual -0.34 |
Profitability
Profit Margin -183.55% | Operating Margin (TTM) -89.11% |
Management Effectiveness
Return on Assets (TTM) -57.08% | Return on Equity (TTM) -934.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 307409171 | Price to Sales(TTM) 5.91 |
Enterprise Value 307409171 | Price to Sales(TTM) 5.91 | ||
Enterprise Value to Revenue 6.15 | Enterprise Value to EBITDA -6.69 | Shares Outstanding 53678800 | Shares Floating 32536478 |
Shares Outstanding 53678800 | Shares Floating 32536478 | ||
Percent Insiders 5.98 | Percent Institutions 75.72 |
Upturn AI SWOT
Scpharmaceuticals Inc
Company Overview
History and Background
scPharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing products that have the potential to transform the way serious diseases are treated, primarily in the acute care setting. Founded in 2013, scPharmaceuticals aims to reduce healthcare costs and improve patient outcomes through subcutaneous delivery systems.
Core Business Areas
- FUROSCIX: FUROSCIX is scPharmaceuticals' lead product, a proprietary, preservative-free formulation of furosemide for subcutaneous administration for the treatment of congestion due to heart failure. It is designed to provide consistent and predictable diuresis compared to IV furosemide, with potential for at-home administration.
Leadership and Structure
The company's leadership team includes individuals with experience in pharmaceutical development, regulatory affairs, and commercialization. The organizational structure is typical of a biotech company, with departments focused on research and development, clinical trials, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- FUROSCIX: FUROSCIX (furosemide injection) for subcutaneous use is indicated for the treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II and III heart failure. Market share is emerging after commercial launch in early 2023. Competitors include oral furosemide and IV furosemide. There is not a direct competitor offering subcutaneous furosemide. scPharmaceuticals holds a unique market position.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The heart failure market is significant and growing due to an aging population and increasing prevalence of chronic diseases.
Positioning
scPharmaceuticals is positioned as an innovator in the treatment of heart failure, offering a novel subcutaneous delivery option. The company aims to capture a portion of the market currently served by IV and oral diuretics.
Total Addressable Market (TAM)
The total addressable market for heart failure treatments is substantial, estimated at billions of dollars annually. scPharmaceuticals is positioned to capture a portion of this TAM by offering a convenient and potentially cost-effective alternative to existing therapies. Exact figures for subcutaneous diuresis are unavailable but IV diuresis spends multiple billions, representing the available TAM opportunity for SC formulation.
Upturn SWOT Analysis
Strengths
- Novel subcutaneous delivery system
- Potential for at-home administration
- Improved patient convenience
- Strong intellectual property protection
- Addresses a significant unmet need in heart failure management
Weaknesses
- Reliance on a single product (FUROSCIX)
- Dependence on successful commercialization
- Requires physician and patient adoption of new technology
- Limited operating history
- Relatively small company size
Opportunities
- Expansion of indications for FUROSCIX
- Development of new subcutaneous drug delivery platforms
- Strategic partnerships with pharmaceutical companies
- Market growth in heart failure treatments
- Potential for international expansion
Threats
- Competition from existing diuretics and other heart failure therapies
- Regulatory hurdles and delays
- Pricing and reimbursement pressures
- Adverse events or safety concerns
- Generic entry if patents are not properly enforced
Competitors and Market Share
Key Competitors
- LLY
- NVS
- VTRS
Competitive Landscape
scPharmaceuticals' advantage lies in its novel subcutaneous delivery system, which differentiates it from traditional diuretics. However, it faces competition from established pharmaceutical companies with greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the recent commercial launch of FUROSCIX.
Future Projections: Future growth is dependent on the successful adoption of FUROSCIX and potential expansion into new markets.
Recent Initiatives: Recent initiatives include expanding the sales force, conducting post-marketing studies, and pursuing regulatory approvals in additional countries.
Summary
scPharmaceuticals is a small company with a promising, novel drug delivery system for heart failure. However, it is early in its commercial trajectory and faces several risks related to market adoption, competition, and regulatory hurdles. FUROSCIX offers advantages over traditional methods, but it must successfully gain trust among physicians and patients. The company's long-term success hinges on securing reimbursement coverage and broadening their market presence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- scPharmaceuticals Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scpharmaceuticals Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2017-11-17 | President, CEO, Principal Executive Officer & Director Mr. John H. Tucker | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | |
Full time employees 162 | |||
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.